Cargando…
The Vaccine World of COVID-19: India’s Contribution
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) eruption has left not only illness and mortality in its wake, but also an overwhelming threat to health policy, human regality, food security, and struggle worldwide. The accessibility and potential distribution of a protective and suc...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695423/ https://www.ncbi.nlm.nih.gov/pubmed/36423038 http://dx.doi.org/10.3390/vaccines10111943 |
_version_ | 1784838056329609216 |
---|---|
author | Chavda, Vivek P. Vihol, Disha R. Solanki, Hetvi K. Apostolopoulos, Vasso |
author_facet | Chavda, Vivek P. Vihol, Disha R. Solanki, Hetvi K. Apostolopoulos, Vasso |
author_sort | Chavda, Vivek P. |
collection | PubMed |
description | The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) eruption has left not only illness and mortality in its wake, but also an overwhelming threat to health policy, human regality, food security, and struggle worldwide. The accessibility and potential distribution of a protective and successful vaccination to communities throughout the world are being considered now not just, as a potential of overcoming these hurdles, but also as an example of human perseverance in the face of catastrophe. A vaccine is the only tool that can efficaciously deal with the COVID-19 catastrophe. Currently, more than 47 vaccines are permitted for emergency use in distinct parts of the world. India will play a significant role in the development of the high-priced Moderna shots and Pfizer Inc, therefore assisting in the immunization of a large portion of the world. Moreover, many of the internationally researched and developed vaccine laboratories seek manufacturing in Indian firms and companies for efficient and low-cost production of vaccines intending to provide to the world, hence, making India, a major role player during these pandemic times. This review highlights the Indian contribution to the globe for COVID-19 management. |
format | Online Article Text |
id | pubmed-9695423 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96954232022-11-26 The Vaccine World of COVID-19: India’s Contribution Chavda, Vivek P. Vihol, Disha R. Solanki, Hetvi K. Apostolopoulos, Vasso Vaccines (Basel) Review The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) eruption has left not only illness and mortality in its wake, but also an overwhelming threat to health policy, human regality, food security, and struggle worldwide. The accessibility and potential distribution of a protective and successful vaccination to communities throughout the world are being considered now not just, as a potential of overcoming these hurdles, but also as an example of human perseverance in the face of catastrophe. A vaccine is the only tool that can efficaciously deal with the COVID-19 catastrophe. Currently, more than 47 vaccines are permitted for emergency use in distinct parts of the world. India will play a significant role in the development of the high-priced Moderna shots and Pfizer Inc, therefore assisting in the immunization of a large portion of the world. Moreover, many of the internationally researched and developed vaccine laboratories seek manufacturing in Indian firms and companies for efficient and low-cost production of vaccines intending to provide to the world, hence, making India, a major role player during these pandemic times. This review highlights the Indian contribution to the globe for COVID-19 management. MDPI 2022-11-17 /pmc/articles/PMC9695423/ /pubmed/36423038 http://dx.doi.org/10.3390/vaccines10111943 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Chavda, Vivek P. Vihol, Disha R. Solanki, Hetvi K. Apostolopoulos, Vasso The Vaccine World of COVID-19: India’s Contribution |
title | The Vaccine World of COVID-19: India’s Contribution |
title_full | The Vaccine World of COVID-19: India’s Contribution |
title_fullStr | The Vaccine World of COVID-19: India’s Contribution |
title_full_unstemmed | The Vaccine World of COVID-19: India’s Contribution |
title_short | The Vaccine World of COVID-19: India’s Contribution |
title_sort | vaccine world of covid-19: india’s contribution |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695423/ https://www.ncbi.nlm.nih.gov/pubmed/36423038 http://dx.doi.org/10.3390/vaccines10111943 |
work_keys_str_mv | AT chavdavivekp thevaccineworldofcovid19indiascontribution AT viholdishar thevaccineworldofcovid19indiascontribution AT solankihetvik thevaccineworldofcovid19indiascontribution AT apostolopoulosvasso thevaccineworldofcovid19indiascontribution AT chavdavivekp vaccineworldofcovid19indiascontribution AT viholdishar vaccineworldofcovid19indiascontribution AT solankihetvik vaccineworldofcovid19indiascontribution AT apostolopoulosvasso vaccineworldofcovid19indiascontribution |